Malaysia Nuclear Drugs Market Facts, Future Scenarios, Growth and Analytical Prospects

Nuclear Drugs Market in Malaysia

The Malaysian Nuclear Drugs Market is expected to reach USD 70.24 Million by 2028, registering a CAGR of 9.86% from 2020 to 2028.

PORTLAND, OREGON, USA, July 24, 2022 / โ€” Nuclear Drugs Market in Malaysia by type, modality, application and end user: opportunity analysis and industry forecast, 2020-2028. Radiopharmaceuticals are radioactive materials or radioisotopes which, when bound to biological molecules, are capable of targeting specific tissues, organs or cells in the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the treatment of diseases. A radiopharmaceutical can be seen as an entity composed of a radionuclide and a carrier molecule with high affinity or binding power to a specific tissue or function of a human organ. Moreover, it may include only the radioisotope itself if it exhibits appropriate biological properties.

๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ:
Cardinal Health, Inc.
Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.)
GE Healthcare
Ion Beam Applications (Ion Beam Applications, SA)
Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
MERCK KGAA (Sigma Aldrich)
Novartis AG (Advanced Accelerator Applications SA), Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH)
Siemens Healthcare GmbH
Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp).

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

๐†๐ž๐ญ ๐”๐ฉ ๐“๐จ ๐Ÿ๐ŸŽ% ๐ƒ๐ข๐ฌ๐œ๐จ๐ฎ๐ง๐ญ, ๐“๐ข๐ฅ๐ฅ ๐ญ๐ก๐ž ๐ƒ๐š๐ญ๐ž ๐Ÿ๐ŸŽ๐ญ๐ก ๐จ๐Ÿ ๐€๐ฎ๐ ๐ฎ๐ฌ๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ.

๐—–๐—ผ๐˜ƒ๐—ถ๐—ฑ-๐Ÿญ๐Ÿต ๐—ฆ๐—ฐ๐—ฒ๐—ป๐—ฎ๐—ฟ๐—ถ๐—ผ:

The nationwide lockdown, government regulations and the continued rise in the infection rate across the country have created a widespread financial impact on hospitals and neurology clinics. There are a large number of hospitals and clinics that have seen a drop in the number of patient visits amid COVID-19, ultimately reducing contact with customers. Radiopharmaceuticals can be used for the detection of COVID-19. They have the potential to provide evidence and clarify conflicting concepts in the use of nonsteroidal anti-inflammatory drugs for COVID-19 patients that is in the research phase. The achievements of radiopharmaceuticals in the diagnosis of COVID-19 infection are expected to help the market gain momentum in the coming years. At the same time, the limited availability of healthcare personnel across the country is another factor that has an adverse effect on the Malaysian nuclear drug market.

๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ

The Malaysian nuclear drugs market is segmented on the basis of type, modality, application and end-user. On the basis of type, the market is divided into diagnostics, therapeutics and biochemical research.

The diagnostics segment dominated the market in 2020 and is expected to continue this trend throughout the forecast period, owing to the increasing incidence of heart conditions and better imaging technique using diagnostic equipment such as SPECT and PET. The increase in the number of cancer patients who require early diagnosis for proper treatment propels the growth of the diagnostics segment.

By modality, the Malaysian nuclear medicine market is divided into SPECT, PET, beta emitters, alpha emitters, brachytherapy and others. The SPECT segment is expected to witness considerable market growth over the forecast period, owing to the increase in the market for medical diagnostics such as cancer, cardiology and neurology. Additionally, obtaining multiple 2D and 3D images found by performing SPECT imaging technique helps in gaining better access to visualization and is useful for physicians.

By application, the Malaysian nuclear medicine market is split into oncology, cardiology, thyroid, neurology and others. The oncology segment is expected to witness substantial growth in the market over the forecast period, owing to the increase in advancements in radiation therapy which has propelled the ease of the process of treating cancerous tumors and increase in the incidence of cancer.

By end user, the Malaysian nuclear medicine market is divided into hospitals, diagnostic centers and research institutes. The hospital and diagnostic center segment is expected to experience significant market growth over the forecast period, owing to the increase in the flow of patients in hospitals and the increased preference for hospitals and diagnostic centers .

๐Š๐„๐˜ ๐…๐ˆ๐๐ƒ๐ˆ๐๐†๐’ ๐Ž๐… ๐“๐‡๐„ ๐’๐“๐”๐ƒ๐˜

โ€ข By type, the diagnostics segment was the largest market contributor in 2020.
โ€ข By modality, the SPECT segment is expected to register the highest revenue shares during the forecast period.
โ€ข By application, the oncology segment is expected to gain the highest revenue shares in the coming years.
โ€ข By end user, hospital and diagnostic center segment expected to generate the highest revenue

๐–๐ž ๐š๐ฅ๐ฌ๐จ ๐Ž๐Ÿ๐Ÿ๐ž๐ซ๐ฌ ๐‘๐ž๐ ๐ข๐จ๐ง๐š๐ฅ ๐‚๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ-

North America Nuclear Drugs Market
Japanese nuclear drug market
South Korea Nuclear Drugs Market
Singapore Nuclear Drugs Market
Australian nuclear drug market
European nuclear drug market
Chinese nuclear drug market
Indonesian nuclear drug market
Taiwan Nuclear Drugs Market

๐Ž๐ญ๐ก๐ž๐ซ ๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ

Single Cell Multiomics Market

medical eyewear market

David Correa
Allied Analytics LLP
write to us here
Visit us on social media:

Source link

Sandy A. Greer